



13 February 2017

**Oxford BioDynamics Plc  
("OBD" or the "Company")**

**Oxford BioDynamics appoints Dr Claudio Carini as an Advisor**

Oxford BioDynamics Plc (AIM: OBD), a revenue-generating biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry, announces that Dr Claudio Carini has been appointed as an Advisor, effective immediately. As part of his role, Claudio will sit on the Company's Scientific Advisory Panel.

Claudio has over 20 years' experience in immunology, drug development, personalised medicine, and biomarkers. Previously, he was Global Head of Clinical Immunology & Biomarkers at Pfizer, and currently holds an Honorary Faculty position at the King's College School of Medicine, London. Claudio has also consulted and sat on many distinguished international advisory boards and committees including the Medical Research Council (UK), F-NIH Biomarkers Consortium, Innovative Medicine Initiative (IMI-EU) and the PML Consortium.

Prior to joining Pfizer, Claudio has served in faculty roles at Harvard University, Johns Hopkins University, University College London and Rome University. Later in his career he held different senior roles at Wyeth, Novartis, Fresenius and Roche. He has also authored over two hundred papers in peer reviewed journals and co-edited three books in the field of personalised medicine. Claudio has received a doctorate in Medicine from Italy and a Ph.D from the University College London. Claudio has also specialist diplomas in Clinical Immunology and Respiratory Medicine from the University of Rome and has also been awarded a fellowship of the Royal College of Pathologists, London.

**Christian Hoyer Millar, CEO of Oxford BioDynamics said:**

"We are delighted that Claudio will be joining the Company as an Advisor. His strong passion in the application of biomarkers in translational medicine and personalised healthcare, and impressive track record in this field will be hugely beneficial to Oxford BioDynamics at this exciting time in our development.

His previous experience in the US will be of great value to us as we continue to build and expand relationships with some of the leading pharma and biotechnology companies globally."

**For further details contact:**

**Oxford BioDynamics Plc**  
Christian Hoyer Millar, CEO  
Katie Long, CFO

**+44 (0)1865 518910**

**FTI Consulting**  
**Financial Public Relations Advisor**  
Julia Phillips  
Brett Pollard  
Natalie Garland-Collins  
Matthew Moss

**+44 (0)20 3727 1000**



**OXFORD BIODYNAMICS**

**Stifel Nicolaus Europe Limited**  
**Nominated Advisor and Broker**

**+44 (0)20 7710 7600**

David Arch  
Jonathan Senior  
Peter Lees  
Ben Maddison

***Notes for Editors***

**About Oxford BioDynamics Plc**

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue-generating biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, *EpiSwitch*<sup>™</sup>, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, *EpiSwitch*<sup>™</sup> can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re-positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit [www.oxfordbiodynamics.com](http://www.oxfordbiodynamics.com).